Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALTNASDAQ:KMDANASDAQ:OPTNNASDAQ:ZYBT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$5.07-1.9%$5.27$3.55▼$11.16$390.46M0.912.88 million shs1.02 million shsKMDAKamada$6.69+1.1%$6.72$4.74▼$9.16$384.54M1.0786,068 shs27,718 shsOPTNOptiNose$9.28+0.2%$7.65$4.82▼$20.03$93.98M-0.8761,875 shs18,755 shsZYBTZhengye Biotechnology$10.44-1.0%$5.41$3.50▼$12.46$492.41MN/A274,433 shs599,368 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune0.00%+11.31%-8.98%-27.36%-28.39%KMDAKamada0.00%+2.92%-2.05%-6.95%+29.15%OPTNOptiNose0.00%+1.20%+1.53%+41.68%-33.14%ZYBTZhengye Biotechnology0.00%+3.78%+93.33%+144.50%+1,043,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune2.1329 of 5 stars3.41.00.00.01.63.30.6KMDAKamada3.9953 of 5 stars3.55.00.00.03.01.72.5OPTNOptiNose3.3075 of 5 stars1.05.00.04.23.22.50.6ZYBTZhengye BiotechnologyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.89Moderate Buy$20.83310.91% UpsideKMDAKamada 3.00Buy$14.67119.23% UpsideOPTNOptiNose 2.00Hold$9.00-3.02% DownsideZYBTZhengye Biotechnology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OPTN, ALT, KMDA, and ZYBT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/21/2025KMDAKamadaBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.003/21/2025OPTNOptiNosePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$15.00 ➝ $9.003/21/2025OPTNOptiNoseHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$18.00 ➝ $9.003/20/2025OPTNOptiNosePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/20/2025OPTNOptiNoseLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$17.00 ➝ $9.003/18/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/14/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/6/2025KMDAKamadaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/3/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.002/28/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K19,523.05N/AN/A$2.75 per share1.84KMDAKamada$160.95M2.39$0.37 per share17.90$4.25 per share1.57OPTNOptiNose$78.23M1.20N/AN/A($11.56) per share-0.80ZYBTZhengye Biotechnology$189.75M2.60N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.45M-$1.34N/AN/AN/A-199,076.92%-55.81%-50.60%5/8/2025 (Estimated)KMDAKamada$8.28M$0.2623.8920.910.979.92%6.30%4.49%5/6/2025 (Estimated)OPTNOptiNose-$35.48M-$2.88N/AN/AN/A-41.16%N/A-27.42%5/13/2025 (Estimated)ZYBTZhengye BiotechnologyN/AN/A0.00∞N/AN/AN/AN/AN/ALatest OPTN, ALT, KMDA, and ZYBT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025KMDAKamada$0.07N/AN/AN/A$154.06 millionN/A5/13/2025Q1 2025OPTNOptiNose-$0.74N/AN/AN/A$17.70 millionN/A5/8/2025Q1 2025ALTAltimmune-$0.36N/AN/AN/A$0.00 millionN/A3/26/2025Q4 2024OPTNOptiNose-$0.70-$0.03+$0.67-$0.03$21.02 million$21.47 million2/27/2025Q4 2024ALTAltimmune-$0.34-$0.33+$0.01-$0.33$0.00 million$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AKMDAKamadaN/AN/AN/AN/AN/AOPTNOptiNoseN/AN/AN/AN/AN/AZYBTZhengye BiotechnologyN/AN/AN/AN/AN/ALatest OPTN, ALT, KMDA, and ZYBT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/5/2025KMDAKamada--$0.203/17/20253/17/20254/7/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A16.8716.87KMDAKamadaN/A4.842.73OPTNOptiNoseN/A0.790.72ZYBTZhengye BiotechnologyN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%KMDAKamada20.38%OPTNOptiNose85.60%ZYBTZhengye BiotechnologyN/AInsider OwnershipCompanyInsider OwnershipALTAltimmune4.10%KMDAKamada36.10%OPTNOptiNose2.30%ZYBTZhengye BiotechnologyN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5077.01 million68.21 millionOptionableKMDAKamada36057.48 million36.73 millionOptionableOPTNOptiNose19010.13 million9.83 millionNot OptionableZYBTZhengye Biotechnology27847.17 millionN/AN/AOPTN, ALT, KMDA, and ZYBT HeadlinesRecent News About These CompaniesShould We Be Cautious About Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) ROE Of 6.9%?April 7, 2025 | finance.yahoo.comZhengye Biotechnology Holding Ltd.April 3, 2025 | wsj.comZhengye Biotechnology Holding Limited (ZYBT)March 27, 2025 | finance.yahoo.comZhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment OptionJanuary 14, 2025 | globenewswire.comZhengye Biotechnology Holding Limited Announces Closing of Initial Public OfferingJanuary 8, 2025 | globenewswire.comZhengye Biotechnology Holding Limited Announces Pricing of Initial Public OfferingJanuary 6, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?4 Healthcare Stocks With Massive Gains—and More to ComeBy Sarah Horvath | March 29, 2025View 4 Healthcare Stocks With Massive Gains—and More to ComeWho Led Buybacks to End 2024? Hint: It Wasn’t Big TechBy Leo Miller | April 8, 2025View Who Led Buybacks to End 2024? Hint: It Wasn’t Big Tech4 Dividend Growth Stocks the Trade Tariffs Can’t TouchBy Thomas Hughes | April 7, 2025View 4 Dividend Growth Stocks the Trade Tariffs Can’t TouchWhich Healthcare Stock Is the Best Buy Right Now?By Nathan Reiff | March 31, 2025View Which Healthcare Stock Is the Best Buy Right Now?OPTN, ALT, KMDA, and ZYBT Company DescriptionsAltimmune NASDAQ:ALT$5.07 -0.10 (-1.93%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$5.10 +0.03 (+0.61%) As of 04/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Kamada NASDAQ:KMDA$6.69 +0.07 (+1.06%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$6.66 -0.03 (-0.37%) As of 04/25/2025 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.OptiNose NASDAQ:OPTN$9.28 +0.02 (+0.22%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$9.28 0.00 (0.00%) As of 04/25/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.Zhengye Biotechnology NASDAQ:ZYBT$10.44 -0.11 (-1.04%) As of 04/25/2025 04:00 PM EasternZhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
